Home›Trial›NCT06911320
🔬NCT06911320Phase 1RECRUITING

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

Study Summary

To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose

Conditions
Healthy Volunteer StudyHepatic ImpairmentRenal Impairment
Interventions / Drugs
Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination
View on ClinicalTrials.gov ↗
Sponsor
AVIR
Atea Pharmaceuticals
Infectious Disease
D38/100
Study Details
Enrollment28 participants
Primary Completion—
Lead SponsorAtea Pharmaceuticals, Inc.
Data Retrieved2026-04-11 02:55:17.105140+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.